SAM LNP S
Alternative Names: SAM-LNP-S; samRNA; Self-amplifying mRNA vaccineLatest Information Update: 28 Apr 2024
At a glance
- Originator Gritstone bio
- Developer Gritstone bio; National Institute of Allergy and Infectious Diseases
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in USA (IM, Injection)
- 11 Oct 2023 Immunogenicity and adverse events data from a phase I in COVID-2019 infections released by Gritstone bio
- 15 Sep 2023 Gritstone Oncology and the National Institute of Allergy and Infectious Diseases complete the phase I CORAL-NIH trial in COVID-2019 infections (Prevention, In adults, In the elderly) in USA (IM, Injection) (NCT04776317)